National Western Life Group Exploring Strategic Alternatives, Bausch Health Surges on U.S. District Court's Decision, Kura Oncology Initiated with a Buy
- May 17th, 2023
- 583 views
National Western Life Group, Inc. (Nasdaq: NWLI) has announced its intention to explore strategic alternatives with the aim of maximizing value for its stockholders. At this stage, no specific decision has been made regarding a sale, merger, or other strategic transaction. The timing and outcome of this review process are uncertain.
$NWLI is currently trading at $378.15, experiencing a substantial increase of $110.86 or 41.47%, following the announcement.
Bausch Health Companies Inc. (NYSE: BHC) said that the U.S. District Court of Delaware has upheld the final judgment regarding Xifaxan 550 mg (used to treat irritable bowel syndrome and diarrhea in adults), which prevents the FDA from approving Norwich Pharmaceuticals' Abbreviated New Drug Application until Oct. 2, 2029.
$BHC is currently trading at $7.66, showing a significant increase of $1.64 or 27.16%.
BTIG Research has initiated coverage on Kura Oncology, Inc. (Nasdaq: KURA) with a Buy rating and a price target of $31
As of now, $KURA is trading at $12.68, reflecting a marginal increase of $0.16 or 1.28%
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Due: Wall Street Eyes Goldman Sachs, Fastenal, FB Financial
April 12th, 2026Treasury Launches Cybersecurity Information Sharing Initiative for the Digital Asset Industry
April 09th, 2026How Eligibility Protection Is Creating New Opportunities for Football Athletes After High School
April 08th, 2026Cryptocurrency and AI Scams Bilk Americans of Billions
April 06th, 2026
Member Login